Market Outlook

Regional and Segment Outlook

North America dominated the cell and gene therapy manufacturing market in 2025, representing more than 52% of the global share. This region leads due to robust biopharma R&D investments and state-of-the-art manufacturing infrastructure, underpinning its status as the largest regional market. Organizations such as the National Institutes of Health (NIH) consistently fund gene therapy research, accelerating product pipelines. Additionally, infrastructure advancements in scalable manufacturing facilities—demonstrated by companies like Novartis and GSK—enable efficient production and faster clinical transitions. Regulatory frameworks by the U.S. FDA also foster innovation through expedited approvals, enhancing market responsiveness. Combined with high healthcare expenditure and a skilled workforce concentrated in biotech hubs, North America offers a dynamic environment where cell and gene therapy manufacturing can thrive, positioning it for sustained growth and investment opportunities.

The United States anchors the North American cell and gene therapy manufacturing market, driven heavily by its unparalleled biopharmaceutical R&D expenditure, which the Biotechnology Innovation Organization (BIO) reports as the highest globally. Leading firms such as Spark Therapeutics and bluebird bio have established cutting-edge manufacturing sites, leveraging the country’s advanced regulatory pathways provided by the U.S. FDA's regenerative medicine advanced therapy (RMAT) designation. Furthermore, strategic collaborations between academic institutions and industry, exemplified by partnerships like that of the University of Pennsylvania with Novartis, bolster innovation ecosystems. This environment enables the U.S. to maintain a dominant role in the regional market, drawing significant investor interest and cementing its leadership in commercializing breakthrough therapies.

Asia Pacific Market Analysis:

Asia Pacific emerged as the fastest-growing region in the cell and gene therapy manufacturing market, registering a robust CAGR of 13.5%. This remarkable growth is primarily driven by the expansion of contract manufacturing capacities coupled with escalating government funding to advance therapy development. These factors have accelerated infrastructure investments and fostered collaboration between public institutions and private entities, enhancing the region’s manufacturing capabilities. Notably, initiatives such as the Asia Pacific Advanced Therapies Alliance’s efforts to harmonize regulatory frameworks have streamlined clinical translation and commercialization. Additionally, rising healthcare expenditure and widespread adoption of innovative biotechnologies in markets like South Korea and Singapore underscore Asia Pacific’s strategic importance. With persistent innovation and increasingly supportive policy environments, the region is poised to unlock substantial opportunities in cell and gene therapy production, attracting global biopharma investments and partnerships.

Japan plays a pivotal role in Asia Pacific’s cell and gene therapy manufacturing market, reflecting the country’s advanced biopharmaceutical infrastructure and proactive governmental support. Japan’s Ministry of Health, Labour and Welfare’s (MHLW) accelerated approval pathways for regenerative medicines incentivize swift commercialization of novel therapies, driving demand for scalable manufacturing solutions. Furthermore, companies such as Takeda Pharmaceutical are investing heavily in manufacturing capacities to meet domestic and export needs. Japan’s aging population is also expanding demand for advanced therapeutic interventions, positioning the country as a vital innovation and production hub. These dynamics reinforce the region’s growth and create a compelling environment for investors eyeing Asia Pacific’s evolving market.

China’s expanding contract manufacturing capacity and substantial government funding uniquely fuel its leadership within Asia Pacific’s cell and gene therapy manufacturing landscape. The Chinese National Medical Products Administration (NMPA) has enacted streamlined regulations to fast-track advanced therapy approvals, fostering rapid technology adoption. Major biopharma players like WuXi AppTec are scaling up cell and gene therapy manufacturing platforms, reflecting the country’s commitment to becoming a global biotech powerhouse. Additionally, China’s large patient population and increasing healthcare investments underpin robust market demand. This environment enables China to not only serve domestic needs but also to influence regional supply chains, greatly amplifying Asia Pacific’s overall competitiveness and innovation potential in cell and gene therapy manufacturing.

Europe Market Trends:

Europe held a commanding share of the cell and gene therapy manufacturing market, driven by robust infrastructure and progressive regulatory frameworks tailored for advanced therapies. The region’s emphasis on personalized medicine and substantial public and private investments foster an innovation-conducive environment. Organizations like the European Medicines Agency (EMA) have streamlined approval processes, enabling faster clinical translation. Additionally, Europe’s diverse demographic profiles and sophisticated healthcare systems boost demand for cutting-edge biologics. Collaborative networks such as the Innovative Medicines Initiative also propel operational advancements and supply chain resilience. These factors collectively ensure a strategic position for Europe as a hub for next-generation therapeutics. Going forward, ongoing digital transformation and sustainable manufacturing priorities offer significant avenues for scaling production and enhancing cost-efficiency.

Germany plays a pivotal role in Europe’s cell and gene therapy manufacturing market, propelled by its advanced biopharmaceutical ecosystem and skilled workforce. The country benefits from supportive government policies, including substantial funding schemes by the Federal Ministry of Education and Research (BMBF) targeting cell therapy innovation. Germany’s industrial landscape, exemplified by companies such as Miltenyi Biotec, advances technology integration and automation in manufacturing. This facilitates efficient scale-up and compliance with stringent quality standards set by the Paul-Ehrlich-Institut. Consequently, Germany strengthens Europe’s overall competitive standing in this sector and attracts multinational collaborations focusing on novel therapeutic modalities.

France occupies a strategic position within Europe’s cell and gene therapy manufacturing market through a growing emphasis on translational research and public-private partnerships. The French government’s initiatives, such as the Plan France Médecine Génomique 2025, have accelerated access to genetic therapies and fostered capacity expansion in manufacturing facilities. Strong support from agencies like the French National Agency for Medicines and Health Products Safety (ANSM) complements the ecosystem, promoting regulatory alignment and innovation. Companies including Cellectis demonstrate France’s leadership in gene editing technologies. As a result, France enhances regional diversity in innovation pathways and adds value to Europe’s integrated supply chain, bolstering the region’s long-term market prospects.